Effects of inositol on oocyte quality in patients affected with polycystic ovary syndrome;Effetti dell'inositolo sulla qualità ovocitaria in pazienti affette da sindrome dell'ovaio policistico

Minerva Ginecologica

Volumn 62, Issue 6, 2010, Pages 525-531

  Ciotta, L ^a   Stracquadanio, M ^a   Pagano, I ^a   Carbonaro, A ^a   Palumbo, M ^a   Gulino, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Fertilization in vitro; Infertility; Inositol; Oocytes; Polycystic ovary syndrome

Indexed keywords

FOLIC ACID; INOSITOL;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ECHOGRAPHY; EMBRYO TRANSFER; FEMALE; HUMAN; HUMAN CELL; OOCYTE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FERTILIZATION IN VITRO; FOLIC ACID; HUMANS; INFERTILITY, FEMALE; INOSITOL; OOCYTES; OVARIAN FOLLICLE; POLYCYSTIC OVARY SYNDROME; SAMPLING STUDIES; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 79952213286     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sattar N, Hopkinson Z, Greer IA. Insulin-sensiting agents in polycystic ovary sindrome. Lancet 1998;351-25.
2. Cianci S. Rivisitando la policistosi ovarica. Aggiornamenti in ostetricia e Ginecologia CIC Edizioni Internazionali, Roma, 1988.
3. Flamigni C, Venturoli S, Porcu E. La sindrome dell'ovaio micropolicistico; Considerazioni cliniche ed eziopatogenetiche. In: Genazzani A, Volpe D. Endocrinologia ginecologica. Fisiopatologia, clinica e Strategie terapeutiche. Bologna: Monduzzi Editore; 1984.
4. Filicori M, Flamigni C, Campaniello E, Meriggiola MC, Michelacci L, Valdiserri A et al. Polycystic ovary sindrome: abnormalities and managements with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Am J Obstet Gynecol 1990;163:1737-42.
5. Arosio M, Persani L, Faglia G. Sindrome dell'ovaio policistico; Malattie endocrine dell'ovaio. Malattie del sistema endocrino e del metabolismo. Milano: McGraw-Hill; 2006.
6. ACOG Committee on Practice Bulletins. ACOG Practice Bulletin: Polycystic Ovary syndrome. Int J Gynecol Obstet 2003,80:335-48.
7. Toscano V. Sindrome dell'ovaio policistico. Manuale di terapia delle malattie endocrine e metaboliche. In: Andreani D, Tamburrano G, editori. Roma: Antonio Delfino Editore; 2000.
8. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-20. (Pubitemid 29196593)
9. Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91:1750-4.
10. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23:700-3. (Pubitemid 350261211)
11. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591-0.
12. Gerli S, Capanna F, Porcaro G. The effect of myo-inositol on ovarian stimulation and in vitro fertilization: a pilot study. Congresso ISGE, Firenze 2008.
13. Knowler WC, Barrett-Connor E, Fowler SE; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346:343-403.
14. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatologic Therapy 2006;19-210-23. (Pubitemid 44386588)
15. Azziz R, Sanchez LA, Knochenhouer ES, Moran C, Lazenby J, Stephens KC et al. Androgen excess in women: Experience with over 1000 consecutive patients. J Clin Endocrinol Metabol 2004;89:453-62. (Pubitemid 38269843)
16. American Diabetes Association. Position statement: Gestational diabetes mellitus. Diabetes Care 2004;7(Supp. 1):S88-S90.
17. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med 1997;157:2413-46.
18. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D- chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300-5. (Pubitemid 44106508)
19. Chiu TTY, Rogers MS, Briton Jones CM, Haines C. Effect of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18:408-16. (Pubitemid 36236278)
20. Chiu TT, Rogers MS, Law EL, Briton-Jones CM, Cheung LP, Haines CJ. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17:1591-6. (Pubitemid 34661813)
21. Goud PT, Goud AP, Oostveldt PV, Dhont M. Presence and dynamic redistribution of type I inositol, 1, 4, 5-triphosphate receptor in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage division. Mol Hum Reprod 1999;5:441-51.
22. Tummon I, Gavrilova-Jordan L, Allemand MC, Session D. Polycistic ovaries and ovarian hyperstimulation syndrome: a systematic review. Acta Obstet Gynecol Scand 2005;84:611-6.
23. Battaglia C, Mancini F, Persico N, Zaccaria V, de Aloysio D. Ultrasound evaluation of PCO, PCOS and OHSS [Review]. Reprod Biomed Online 2004,9:614-9.
24. Iuorno MJ, Jacubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G et al. Effect of D-chiro Inositol in lean women with polycistyc ovary syndrome. Endocr Pract 2002;8:417-23. (Pubitemid 35423128)